摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-吡咯-1-基苯甲酰基氯化物 | 220769-82-4

中文名称
4-吡咯-1-基苯甲酰基氯化物
中文别名
——
英文名称
4-(1H-pyrrol-1-yl)benzoyl chloride
英文别名
4-pyrrol-1-yl-benzoyl chloride;4-pyrrol-1-ylbenzoyl chloride
4-吡咯-1-基苯甲酰基氯化物化学式
CAS
220769-82-4
化学式
C11H8ClNO
mdl
——
分子量
205.644
InChiKey
UDJKUSHVCQXOCH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    22
  • 氢给体数:
    0
  • 氢受体数:
    1

SDS

SDS:05684cdd6fc3c027b1f032b096008c3c
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-吡咯-1-基苯甲酰基氯化物盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下, 以 二氯甲烷 为溶剂, 反应 24.0h, 生成 2-(4-(1H-pyrrol-1-yl)phenyl)-4-benzyloxazol-5(4H)-one
    参考文献:
    名称:
    定向核al钯催化与非共轭烯烃催化,对映选择性的α-内酯与非共轭烯烃的α-烷基化反应。
    摘要:
    描述了钯(II)催化的内酯与非共轭烯烃的对映选择性α-烷基化。该反应使用手性BINOL衍生的磷酸作为立体诱导的来源,并且在烯烃上附加了可裂解的双齿导向基团,以控制区域选择性并稳定催化循环中的核钯烷基钯(II)中间体。人们发现,在最佳反应条件下,各种各样的内酯都具有相容性,从而能够以高收率和高对映选择性提供带有α,α-二取代的α-氨基酸衍生物的产物。
    DOI:
    10.1002/anie.201814272
  • 作为产物:
    描述:
    4-(1-吡咯烷基)苯甲酸氯化亚砜 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.5h, 以60%的产率得到4-吡咯-1-基苯甲酰基氯化物
    参考文献:
    名称:
    Hallikeri; Joshi; More, Uttam A., Indian Journal of Heterocyclic Chemistry, 2014, vol. 23, # 3, p. 249 - 252
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Benzoheterocyclic derivatives
    申请人:Otsuka Pharmaceuticals Co., Ltd.
    公开号:US06335327B1
    公开(公告)日:2002-01-01
    A benzoheterocyclic derivative of the following formula [1]: and pharmaceutically acceptable salts thereof, which show excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as a vasopressin antagonist, vasopressin agonist or oxytocin antagonist.
    以下是该句子的中文翻译: 一种苯并杂环衍生物,其化学式如下: 及其药用盐,表现出优异的抗加压素活性、加压素激动活性和催产素拮抗活性,可用作加压素拮抗剂、加压素激动剂或催产素拮抗剂。
  • [EN] PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] ANTAGONISTES DE RECEPTEUR DE LA PROSTAGLANDINE D2 POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
    申请人:MILLENNIUM PHARM INC
    公开号:WO2005100321A1
    公开(公告)日:2005-10-27
    Disclosed herein are compounds represented by Structural Formula: (I) and (I-A). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply 'CRTH2' for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.
    本文披露了由结构式(I)和(I-A)表示的化合物。还披露了利用这些化合物抑制称为趋化剂受体同源分子表达在Th2上的G蛋白偶联受体,简称为'CRTH2',用于治疗炎症性疾病。结构式(I)和(I-A)中的变量在此处被定义。
  • PGD2 receptor antagonists for the treatment of inflammatory diseases
    申请人:Ghosh Shomir
    公开号:US20050256158A1
    公开(公告)日:2005-11-17
    Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.
    本文揭示了由结构式(I)和(I-A)表示的化合物:还披露了利用这些化合物抑制称为Th2表达的G蛋白偶联受体的化学引诱受体同源分子,简称“CRTH2”,用于治疗炎症性疾病。结构式(I)和(I-A)中的变量在此处被定义。
  • Pesticidal Carboxamides
    申请人:Mihara Jun
    公开号:US20120149910A1
    公开(公告)日:2012-06-14
    The object of the present invention is to provide novel carboxamides which exhibit an excellent pesticidal activity as pesticides. Disclosed are the carboxamides represented by the following Formula (I): wherein each substituent is as defined in the specification, and use thereof as pesticides and animal parasite controlling agents.
    本发明的目的是提供一种新型的羧酰胺,作为杀虫剂表现出优异的杀虫活性。本发明揭示的是由下式(I)表示的羧酰胺,其中每个取代基如规范中所定义,并将其用作杀虫剂和动物寄生虫控制剂。
  • Novel 3,4-Isoxazolediamides as Potent Inhibitors of Chaperone Heat Shock Protein 90
    作者:Riccardo Baruchello、Daniele Simoni、Giuseppina Grisolia、Giuseppina Barbato、Paolo Marchetti、Riccardo Rondanin、Stefania Mangiola、Giuseppe Giannini、Tiziana Brunetti、Domenico Alloatti、Grazia Gallo、Andrea Ciacci、Loredana Vesci、Massimo Castorina、Ferdinando M. Milazzo、Maria L. Cervoni、Mario B. Guglielmi、Marcella Barbarino、Rosanna Foderà、Claudio Pisano、Walter Cabri
    DOI:10.1021/jm201155e
    日期:2011.12.22
    A structural investigation on the isoxazole scaffold led to the discovery of 3,4-isoxazolediamide compounds endowed with potent Hsp90 inhibitory properties. We have found that compounds possessing a nitrogen atom directly attached to the C-4 heterocycle ring possess in vitro Hsp90 inhibitory properties at least comparable to those of the structurally related 4,S-diarylisoxazole derivatives. A group of compounds from this series of diamides combine potent binding affinity and cell growth inhibitory activity in both series of alkyl- and aryl- or heteroarylarnides, with IC50 in the low nanomolar range. The 3,4-isoxazolediamides were also very effective in causing dramatic depletion of the examined client proteins and, as expected for the Hsp90 inhibitors, always induced a very strong increase in the expression levels of the chaperone Hsp70. In vivo studies against human epidermoid carcinoma A431 showed an antitumor effect of morpholine derivative 73 comparable to that induced by the reference compound 10.
查看更多